Next week in Concord, New Hampshire, the Centers for Disease Control and Prevention (CDC), its Advisory Committee on Immunization Practices (ACIP), and The Keystone Center will kick off a four-city series of “community engagement meetings” to examine adding the infant meningococcal vaccine to the childhood vaccine schedule. The reason for this divergence from the CDC’s normal approval process: cost-effectiveness.
If the CDC does not add the meningococcal vaccine to the childhood schedule, it would be the first time in history a Food and Drug Administration (FDA)–approved vaccine was excluded. It would also be the first use of cost-effectiveness analysis under Obamacare.
As Benjamin Domenech, managing editor of The Heartland Institute’s Health Care News, stated in his May 23 Washington Examiner piece, “Whether this vaccine is added to the infant schedule or not, for ACIP not to at least partially recommend a vaccine whose safety has been endorsed by the FDA makes for a dangerous precedent. It would be a sign that decisions about such vaccines will now be made by those with green eyeshades, not stethoscopes.”
The CDC should return to its mission of disease prevention and let an FDA–approved drug into the market for parents and doctors to decide their children’s care.
To attend the New Hampshire meeting, register at http://keystone.org/registration/concord.